Evofem Biosciences has announced that the U.S. Department of Veterans Affairs has awarded the Company a contract for the purchase of Phexxi for a five-year period beginning December 15, 2020. Saundra Pelletier, CEO of Evofem Biosciences, said, “This award is an important milestone in our ongoing effort to create the broadest access to Phexxi for all patients. We have achieved coverage for 55% of…
